Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $75 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Pfizer (NYSE:PFE) and maintained a $75 price target.
August 30, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $75.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Pfizer's stock. The maintained price target of $75 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100